Sophia Genetics reported a 16 percent year-over-year revenue increase in Q2, totaling $18.3 million, fueled by growth outside the biopharma sector and expansion in genomic analysis volumes. The company expanded its multi-year collaboration with AstraZeneca to apply AI-driven tools to breast cancer research, promising to generate real-world evidence to improve therapeutic decision-making. The AstraZeneca partnership is the largest contract in Sophia Genetics' history, reflecting deepening integration of AI in oncology diagnostics. The company’s net loss widened slightly, with increased R&D investment supporting platform advancements.